<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104556</url>
  </required_header>
  <id_info>
    <org_study_id>STRONG-MitraClip 01</org_study_id>
    <nct_id>NCT03104556</nct_id>
  </id_info>
  <brief_title>Silent sTROke duriNG MitraClip Implantation</brief_title>
  <acronym>STRONG</acronym>
  <official_title>Silent sTROke duriNG MitraClip Implantation - STRONG-MitraClip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MitraClip-procedure offers an interventional treatment for high risk patients with severe&#xD;
      symptomatic mitral regurgitation. The number of new cerebral ischemic lesions without&#xD;
      clinical manifestations is high. The aim of this study is to determine the frequency of&#xD;
      cerebral embolisms and cerebral lesions during the MitraClip-procedure using transcranial&#xD;
      doppler ultrasound and magnetic resonance imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mitral regurgitation is the second most common manifestation of valvular heart disease in&#xD;
      adults. Surgical reconstruction is considered treatment of choice. For some patients the&#xD;
      surgical risk is to high an operation is refused. For those Patients the MitraClip system&#xD;
      (Abbott Vascular, Menlo Park, CA, USA) offers a much less invasive treatment option.&#xD;
      Occurrence of a stroke or transient ischemic attack (TIA) is one of the potential&#xD;
      complications during this procedure. 1% of all patients have an acute stroke. The number of&#xD;
      new ischemic lesions without clinical manifestations is much higher (up to 85%). The impact&#xD;
      of these lesions on the global cognitive function is unclear. The aim of this study is to&#xD;
      determine the frequency of cerebral embolisms related to predefined procedural intervals and&#xD;
      postprocedural cerebral lesions using Transcranial Doppler ultrasound and magnetic resonance&#xD;
      imaging. Furthermore we want to study the correlation between cerebral embolisms seen as high&#xD;
      intensity signals in transcranial duplex ultrasound and cerebral lesions seen in the cMRT.&#xD;
      The results should build a basis for further studies that want to reduce the amount of&#xD;
      cerebral lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Actual">December 3, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of high intensity signals (HITS) during the predefined procedural intervals</measure>
    <time_frame>during the procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total amount of high intensity signals and cerebral lesions related to primary and secondary mitral regurgitation</measure>
    <time_frame>0-72h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localizations of cerebral lesions after MitraClip-procedure</measure>
    <time_frame>0-72h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri- and postprocedural stroke</measure>
    <time_frame>0-72h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium after MitraClip</measure>
    <time_frame>0-72h</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Silent Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing the MitraClip between April 2017 December 2019 procedure due to a&#xD;
        severe mitral regurgitation will be enrolled in our study. All patients will be assigned to&#xD;
        either a surgical procedure or the MitraClip-procedure by an interdisciplinary heart team&#xD;
        according to current guidelines irrespective of this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients undergoing a MitraClip-procedure due to mitral regurgitation in the study period&#xD;
        Written consent Procedure recommended by a Cardio-Thoracic Surgery Conference&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who are not able to give consent Patients &lt;18 years Participation in another&#xD;
        interventional Trial Pregnant or lactating females Contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Lauten, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charite Kardiologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 1, 2017</study_first_submitted>
  <study_first_submitted_qc>April 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Alexander Lauten</investigator_full_name>
    <investigator_title>Prof. Dr. med. A. Lauten</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

